目的 探讨强化降压治疗对2型糖尿病患者病死率及心血管和肾脏预后的影响,并阐明其疗效。方法 通过搜索PubMed、EMBASE、科学引文索引和Cochrane图书馆数据库,以确定符合研究纳入标准的随机对照试验(RCT)。两名调查人员独立提取并汇总纳入试验的相关数据,并采用随机效应模型计算所有效应指标的估计值。结果 纳入16项随机对照试验。Meta分析显示,强化降压治疗与非强化降压治疗相比,可显著降低全因死亡风险[相对危险度(RR),0.82;95%CI,0.70~0.96]、主要心血管事件(RR,0.82;95%CI,0.73~0.92,心肌梗死(RR,0.86;95%CI,0.77~0.96)、卒中(RR,0.72;95%CI,0.60~0.88,心血管死亡事件(RR,0.73;95%CI,0.58~0.92)和蛋白尿进展(RR,0.91,95%CI,0.84~0.98)。然而,强化降压治疗对非心血管死亡(RR,0.97;95%CI,0.79~1.20)、心力衰竭(HF)(RR,0.88;95%CI,0.71~1.08)和终末期肾病(ESKD)(RR,1.00;95%CI,0.75~1.33)没有明显影响。亚组分析显示,在大多数患者组中,全因病死率的降低都是一致的,即使在收缩压低于140 mmHg的患者中,强化降压治疗也有明显益处。结论 对2型糖尿病而言,强化降压治疗好处较多,但还需要进一步研究,以评估低于目前推荐的强化降压治疗血压值的益处和危害。
Abstract
Objective To study the effect of intensive BP lowering therapy on the mortality and cardiovascular and renal prognosis of type 2 diabetic patients.Methods The randomized controlled trials (RCTs) that met the inclusion criteria of the study were retrieved by searching PubMed,EMBASE,Scientific Citation Index and Cochrane Library databases.Two investigators independently extracted and collected the related data from the included trials,and used the random effects model to calculate the estimated values of each effect indicator.Results Sixteen randomized controlled trials were included.Meta-analysis showed that intensive BP control reduced the risk of all-cause mortality [relative risk (RR),0.82;95% CI,0.70-0.96],major cardiovascular events (RR,0.82;95% CI,0.73-0.92,myocardial infarction (RR,0.86;95% CI,0.77-0.96),stroke (RR,0.72;95% CI,0.60-0.88,cardiovascular death events (RR,0.73;95% CI,0.58-0.92),and the progression of albuminuria (RR,0.91 95% CI,0.84-0.98) more significantly than the less intensive BP lowering therapy did.However,intensive BP lowering treatment had no significant effect on non-cardiovascular death (RR,0.97;95% CI,0.79-1.20),heart failure (HF) (RR,0.88;95% CI,0.71-1.08) or end-stage kidney disease (ESKD) (RR,1.00;95% CI,0.75-1.33).The reduced all-cause mortality in subgroup analysis was consistent across most patient groups.Moreover,in patients with systolic blood pressure lower than 140 mmHg,intensive BP control was of obvious benefit.Conclusions Our data shows that intensive BP lowering control is more conducive to patients with type 2 diabetes than less intensive control.However,more research is needed to clarify the benefits and hazards of BP targets lower than currently recommended in intensive BP lowering treatment.
关键词
强化降压治疗 /
Meta分析 /
2型糖尿病 /
死亡率
Key words
intensive BP lowering treatment /
meta-analysis /
type 2 diabetes /
mortality
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Xu Y,Wang L,He J,et al.Prevalence and control of diabetes in chinese adults[J].JAMA,2013,310(9):948-959.
[2] Wild S,Roglic G,Green A,et al.Global prevalence of diabetes:estimates for the year 2000 and projections for 2030[J].Diabetes Care,2004,27(5):1047-1053.
[3] Woodward M,Zhang X,Barzi F,et al.The effects of diabetes on the risks of major cardiovascular diseases and death in the asia-pacific region[J].Diabetes Care,2003,26(2):360-366.
[4] Stamler J,Vaccaro O,Neaton J D,et al.Diabetes,other risk factors,and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial[J].Diabetes Care,1993,16(2):434-444.
[5] Assmann G,Cullen P,Schulte H.Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular munster (procam) study[J].Circulation,2002,105(3):310-315.
[6] Mancia G,Fagard R,Narkiewicz K,et al.2013 esh/esc guidelines for the management of arterial hypertension:the task force for the management of arterial hypertension of the european society of hypertension (esh) and of the european society of cardiology (esc)[J].J Hypertens,2013,31(7):1281-1357.
[7] James P A,Oparil S,Carter B L,et al.2014 evidence-based guideline for the management of high blood pressure in adults:report from the panel members appointed to the eighth joint national committee (jnc 8)[J].JAMA,2014,311(5):507-520.
[8] Whelton P K,Carey R M,Aronow W S,et al.2017 acc/aha/aapa/abc/acpm/ags/apha/ash/aspc/nma/pcna guideline for the prevention,detection,evaluation,and management of high blood pressure in adults:a report of the american college of cardiology/american heart association task force on clinical practice guidelines[J].J Am Coll Cardiol,2018,71(19):e127-e248.
[9] Schrier R W,Estacio R O,Esler A,et al.Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria,retinopathy and strokes[J].Kidney Int,2002,61(3):1086-1097.
[10] Berthet K,Neal B C,Chalmers J P,et al.Reductions in the risks of recurrent stroke in patients with and without diabetes:the progress trial[J].Blood Press,2004,13(1):7-13.
[11] Estacio R O,Coll J R,Tran Z V,et al.Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes[J].Am J Hypertens,2006,19(12):1241-1248.
[12] Patel A,Group A C,MacMahon S,et al.Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the advance trial):a randomised controlled trial[J].Lancet,2007,370(9590):829-840.
[13] Ogihara T,Saruta T,Rakugi H,et al.Target blood pressure for treatment of isolated systolic hypertension in the elderly:valsartan in elderly isolated systolic hypertension study[J].Hypertension,2010,56(2):196-202.
[14] Group A S,Cushman W C,Evans G W,et al.Effects of intensive blood-pressure control in type 2 diabetes mellitus[J].N Engl J Med,2010,362(17):1575-1585.
[15] Xie X,Atkins E,Lv J,et al.Effects of intensive blood pressure lowering on cardiovascular and renal outcomes:updated systematic review and meta-analysis[J].Lancet,2016,387(10017):435-443.
[16] Thomopoulos C,Parati G,Zanchetti A.Effects of blood-pressure-lowering treatment on outcome incidence in hypertension:10 - should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials[J].J Hypertens,2017,35(5):922-944.
[17] Brunstrom M,Carlberg B.Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus:systematic review and meta-analyses[J].BMJ,2016,352:717.
[18] Emdin C A,Rahimi K,Neal B,et al.Blood pressure lowering in type 2 diabetes:a systematic review and meta-analysis[J].JAMA,2015,313(6):603-615.
[19] Moher D,Shamseer L,Clarke M,et al.Preferred reporting items for systematic review and meta-analysis protocols (prisma-p) 2015 statement[J].Syst Rev,2015,4:1.
[20] Higgins J P,Altman D G,Gotzsche P C,et al.The cochrane collaboration's tool for assessing risk of bias in randomised trials[J].BMJ,2011,343:5928.
[21] Higgins J P,Thompson S G,Deeks J J,et al.Measuring inconsistency in meta-analyses[J].BMJ,2003,327(7414):557-560.
[22] Piepoli M F,Hoes A W,Agewall S,et al.2016 european guidelines on cardiovascular disease prevention in clinical practice:the sixth joint task force of the european society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts)developed with the special contribution of the european association for cardiovascular prevention &rehabilitation (eacpr)[J].Eur Heart J,2016,37(29):2315-2381.
[23] Reboldi G,Gentile G,Angeli F,et al.Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes:a meta-analysis in 73,913 patients[J].J Hypertens,2011,29(7):1253-1269.
[24] Malhotra R,Nguyen H A,Benavente O,et al.Association between more intensive vs less intensive blood pressure lowering and risk of mortality in chronic kidney disease stages 3 to 5:a systematic review and meta-analysis[J].JAMA Intern Med,2017,177(10):1498-1505.
[25] Thomopoulos C,Parati G,Zanchetti A.Effects of blood pressure lowering on outcome incidence in hypertension:3.Effects in patients at different levels of cardiovascular risk--overview and meta-analyses of randomized trials[J].J Hypertens,2014,32(12):2305-2314.
[26] Group S R,Wright J T,Williamson J D,et al.A randomized trial of intensive versus standard blood-pressure control[J].N Engl J Med,2015,373(22):2103-2116.
基金
军队卫生科学研究专项资助(批准号:16BJZ15)
PDF(677 KB)
